biostudies-literatureYang YLMinistry of Science and Technology, Taiwan5893https://www.ebi.ac.uk/biostudies/studies/S-EPMC7960737biostudies-literatureUnknown11(1)Improvement in outcomes of children with acute myeloid leukemia (AML) is attributed to several refinements in clinical management. We evaluated treatment outcomes of Taiwanese pediatric AML patients in the past 20 years. Overall, 860 de novo AML patients aged 0-18 years and registered in the Childhood Cancer Foundation of R.O.C during January 1996-December 2019 were included. Survival analysis was performed to identify factors that improved treatment outcomes. Regardless of treatment modalities used, patients during 2008-2019 had better 5-year event-free survival (EFS) and overall survival (OS) rates than patients during 1996-2007. For patients received the TPOG-AML-97A treatment, only 5-year OS rates were significantly different between patients diagnosed before and after 2008. Patients wScientific reportsTreatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan.PMC7960737MOST-109023140B0002-156Chen JSWu KHYen HJYang CPHsiao CCLin KHHo WLChen YCJou STHung GYPeng CTYeh TCLiu HCChen RLLin MTWang JLWeng TFChao YHChang YHLu MYHuang FLLiang DCWang LYWang SCSheen JMChao YYHou JYCheng SNLin CYChang HHChang TTChou SWJaing THLin DTHuang THChang TKChen HYYang SHYang YLChen SHChen BWHung IJCheng CNHsieh YLfalseTreatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan.Improvement in outcomes of children with acute myeloid leukemia (AML) is attributed to several refinements in clinical management. We evaluated treatment outcomes of Taiwanese pediatric AML patients in the past 20 years. Overall, 860 de novo AML patients aged 0-18 years and registered in the Childhood Cancer Foundation of R.O.C during January 1996-December 2019 were included. Survival analysis was performed to identify factors that improved treatment outcomes. Regardless of treatment modalities used, patients during 2008-2019 had better 5-year event-free survival (EFS) and overall survival (OS) rates than patients during 1996-2007. For patients received the TPOG-AML-97A treatment, only 5-year OS rates were significantly different between patients diagnosed before and after 2008. Patients w2021-01-01T00:00:00Z2021 Mar2025-04-22T10:51:52.826Z2025-04-05T23:40:16.965ZS-EPMC79607373372333810.1038/s41598-021-85321-3